Cargando…
The Impact of COVID-19 on Time-to-treatment in Pancreatic Adenocarcinoma: A Single Institutional Experience
Autores principales: | Sugumar, Kavin, Cao, Lifen, Hue, Jonathan J., Rothermel, Luke, Ocuin, Lee M., Ammori, John B., Hardacre, Jeffrey M., Winter, Jordan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531623/ http://dx.doi.org/10.1016/j.jamcollsurg.2021.08.306 |
Ejemplares similares
-
The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis
por: Sugumar, Kavin, et al.
Publicado: (2021) -
Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer
por: Hue, Jonathan J., et al.
Publicado: (2021) -
Development and validation of the OSASH score to predict overall survival of hepatocellular carcinoma after surgical resection: a dual-institutional study
por: Wei, Hong, et al.
Publicado: (2023) -
Hyperlipasemia in Hospitalized COVID-19 Patients
por: Kenner, Maria, et al.
Publicado: (2021) -
Small single perivascular hepatocellular carcinoma: comparisons of radiofrequency ablation and microwave ablation by using propensity score analysis
por: An, Chao, et al.
Publicado: (2021)